APO Research
Talk to an analyst

APO RESEARCH · REPORT

Spine Osteoarthritis Pain Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Spine Osteoarthritis Pain Drug Industry Research Report 2026

20 December 2025135 pages

Choose your research edition.

Industry ResearchSpine Osteoarthritis Pain Drug Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Spine Osteoarthritis Pain Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Spine Osteoarthritis Pain Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spine Osteoarthritis Pain Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Spine Osteoarthritis Pain Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Spine Osteoarthritis Pain Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Spine Osteoarthritis Pain Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Spine Osteoarthritis Pain Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Spine Osteoarthritis Pain Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Spine Osteoarthritis Pain Drug include Abbott, TEVA, Sanofi, Johnson and Johnson, Novartis, Mylan, Eli Lilly, Hengrui Pharmaceutical and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Spine Osteoarthritis Pain Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Spine Osteoarthritis Pain Drug Market by Company

Abbott

TEVA

Sanofi

Johnson and Johnson

Novartis

Mylan

Eli Lilly

Hengrui Pharmaceutical

Pfizer

GlaxoSmithKline

Daiichi Sankyo

Bayer

Tide Pharmaceutical

Iroko Pharmaceuticals

Horizon Pharma

Astellas Pharma

Almatica Pharma

Abiogen Pharma

Spine Osteoarthritis Pain Drug Segment by Type

Injection

External

Oral

Spine Osteoarthritis Pain Drug Segment by Application

Medical Care

Personal Care

Spine Osteoarthritis Pain Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spine Osteoarthritis Pain Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spine Osteoarthritis Pain Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spine Osteoarthritis Pain Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Spine Osteoarthritis Pain Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Spine Osteoarthritis Pain Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Spine Osteoarthritis Pain Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Spine Osteoarthritis Pain Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Spine Osteoarthritis Pain Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Spine Osteoarthritis Pain Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Spine Osteoarthritis Pain Drug Revenue of Manufacturers (2021-2026) Table 9. Global Spine Osteoarthritis Pain Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Spine Osteoarthritis Pain Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Spine Osteoarthritis Pain Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Spine Osteoarthritis Pain Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Spine Osteoarthritis Pain Drug, Product Type & Application Table 14. Global Spine Osteoarthritis Pain Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Spine Osteoarthritis Pain Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Abbott Company Information Table 19. Abbott Business Overview Table 20. Abbott Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Abbott Spine Osteoarthritis Pain Drug Product Portfolio Table 22. Abbott Recent Developments Table 23. TEVA Company Information Table 24. TEVA Business Overview Table 25. TEVA Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. TEVA Spine Osteoarthritis Pain Drug Product Portfolio Table 27. TEVA Recent Developments Table 28. Sanofi Company Information Table 29. Sanofi Business Overview Table 30. Sanofi Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Sanofi Spine Osteoarthritis Pain Drug Product Portfolio Table 32. Sanofi Recent Developments Table 33. Johnson and Johnson Company Information Table 34. Johnson and Johnson Business Overview Table 35. Johnson and Johnson Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Johnson and Johnson Spine Osteoarthritis Pain Drug Product Portfolio Table 37. Johnson and Johnson Recent Developments Table 38. Novartis Company Information Table 39. Novartis Business Overview Table 40. Novartis Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Novartis Spine Osteoarthritis Pain Drug Product Portfolio Table 42. Novartis Recent Developments Table 43. Mylan Company Information Table 44. Mylan Business Overview Table 45. Mylan Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Mylan Spine Osteoarthritis Pain Drug Product Portfolio Table 47. Mylan Recent Developments Table 48. Eli Lilly Company Information Table 49. Eli Lilly Business Overview Table 50. Eli Lilly Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Eli Lilly Spine Osteoarthritis Pain Drug Product Portfolio Table 52. Eli Lilly Recent Developments Table 53. Hengrui Pharmaceutical Company Information Table 54. Hengrui Pharmaceutical Business Overview Table 55. Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Product Portfolio Table 57. Hengrui Pharmaceutical Recent Developments Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Pfizer Spine Osteoarthritis Pain Drug Product Portfolio Table 62. Pfizer Recent Developments Table 63. GlaxoSmithKline Company Information Table 64. GlaxoSmithKline Business Overview Table 65. GlaxoSmithKline Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. GlaxoSmithKline Spine Osteoarthritis Pain Drug Product Portfolio Table 67. GlaxoSmithKline Recent Developments Table 68. Daiichi Sankyo Company Information Table 69. Daiichi Sankyo Business Overview Table 70. Daiichi Sankyo Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Daiichi Sankyo Spine Osteoarthritis Pain Drug Product Portfolio Table 72. Daiichi Sankyo Recent Developments Table 73. Bayer Company Information Table 74. Bayer Business Overview Table 75. Bayer Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Bayer Spine Osteoarthritis Pain Drug Product Portfolio Table 77. Bayer Recent Developments Table 78. Tide Pharmaceutical Company Information Table 79. Tide Pharmaceutical Business Overview Table 80. Tide Pharmaceutical Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Tide Pharmaceutical Spine Osteoarthritis Pain Drug Product Portfolio Table 82. Tide Pharmaceutical Recent Developments Table 83. Iroko Pharmaceuticals Company Information Table 84. Iroko Pharmaceuticals Business Overview Table 85. Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Product Portfolio Table 87. Iroko Pharmaceuticals Recent Developments Table 88. Horizon Pharma Company Information Table 89. Horizon Pharma Business Overview Table 90. Horizon Pharma Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Horizon Pharma Spine Osteoarthritis Pain Drug Product Portfolio Table 92. Horizon Pharma Recent Developments Table 93. Astellas Pharma Company Information Table 94. Astellas Pharma Business Overview Table 95. Astellas Pharma Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Astellas Pharma Spine Osteoarthritis Pain Drug Product Portfolio Table 97. Astellas Pharma Recent Developments Table 98. Almatica Pharma Company Information Table 99. Almatica Pharma Business Overview Table 100. Almatica Pharma Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Almatica Pharma Spine Osteoarthritis Pain Drug Product Portfolio Table 102. Almatica Pharma Recent Developments Table 103. Abiogen Pharma Company Information Table 104. Abiogen Pharma Business Overview Table 105. Abiogen Pharma Spine Osteoarthritis Pain Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Abiogen Pharma Spine Osteoarthritis Pain Drug Product Portfolio Table 107. Abiogen Pharma Recent Developments Table 108. Global Spine Osteoarthritis Pain Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Spine Osteoarthritis Pain Drug Sales by Region (2021-2026) & (k units) Table 110. Global Spine Osteoarthritis Pain Drug Sales Market Share by Region (2021-2026) Table 111. Global Spine Osteoarthritis Pain Drug Sales by Region (2027-2032) & (k units) Table 112. Global Spine Osteoarthritis Pain Drug Sales Market Share by Region (2027-2032) Table 113. Global Spine Osteoarthritis Pain Drug Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Region (2021-2026) Table 115. Global Spine Osteoarthritis Pain Drug Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Region (2027-2032) Table 117. North America Spine Osteoarthritis Pain Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Spine Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 119. North America Spine Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 120. North America Spine Osteoarthritis Pain Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Spine Osteoarthritis Pain Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Spine Osteoarthritis Pain Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Spine Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 124. Europe Spine Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 125. Europe Spine Osteoarthritis Pain Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Spine Osteoarthritis Pain Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Spine Osteoarthritis Pain Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Spine Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 129. Asia Pacific Spine Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 130. Asia Pacific Spine Osteoarthritis Pain Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Spine Osteoarthritis Pain Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Spine Osteoarthritis Pain Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Spine Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 134. South America Spine Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 135. South America Spine Osteoarthritis Pain Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Spine Osteoarthritis Pain Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Spine Osteoarthritis Pain Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Spine Osteoarthritis Pain Drug Sales by Country (2021-2026) & (k units) Table 139. Middle East and Africa Spine Osteoarthritis Pain Drug Sales by Country (2027-2032) & (k units) Table 140. Middle East and Africa Spine Osteoarthritis Pain Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Spine Osteoarthritis Pain Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Spine Osteoarthritis Pain Drug Sales by Type (2021-2026) & (k units) Table 143. Global Spine Osteoarthritis Pain Drug Sales by Type (2027-2032) & (k units) Table 144. Global Spine Osteoarthritis Pain Drug Sales Market Share by Type (2021-2026) Table 145. Global Spine Osteoarthritis Pain Drug Sales Market Share by Type (2027-2032) Table 146. Global Spine Osteoarthritis Pain Drug Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Spine Osteoarthritis Pain Drug Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2026) Table 149. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Type (2027-2032) Table 150. Global Spine Osteoarthritis Pain Drug Price by Type (2021-2026) & (US$/unit) Table 151. Global Spine Osteoarthritis Pain Drug Price by Type (2027-2032) & (US$/unit) Table 152. Global Spine Osteoarthritis Pain Drug Sales by Application (2021-2026) & (k units) Table 153. Global Spine Osteoarthritis Pain Drug Sales by Application (2027-2032) & (k units) Table 154. Global Spine Osteoarthritis Pain Drug Sales Market Share by Application (2021-2026) Table 155. Global Spine Osteoarthritis Pain Drug Sales Market Share by Application (2027-2032) Table 156. Global Spine Osteoarthritis Pain Drug Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Spine Osteoarthritis Pain Drug Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2026) Table 159. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Application (2027-2032) Table 160. Global Spine Osteoarthritis Pain Drug Price by Application (2021-2026) & (US$/unit) Table 161. Global Spine Osteoarthritis Pain Drug Price by Application (2027-2032) & (US$/unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Spine Osteoarthritis Pain Drug Distributors List Table 165. Spine Osteoarthritis Pain Drug Customers List Table 166. Spine Osteoarthritis Pain Drug Industry Trends Table 167. Spine Osteoarthritis Pain Drug Industry Drivers Table 168. Spine Osteoarthritis Pain Drug Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Spine Osteoarthritis Pain Drug Product Image Figure 5. Global Spine Osteoarthritis Pain Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Spine Osteoarthritis Pain Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Spine Osteoarthritis Pain Drug Sales (2021-2032) & (k units) Figure 8. Global Spine Osteoarthritis Pain Drug Average Price (US$/unit) & (2021-2032) Figure 9. Injection Product Image Figure 10. External Product Image Figure 11. Oral Product Image Figure 12. Medical Care Product Image Figure 13. Personal Care Product Image Figure 14. Global Spine Osteoarthritis Pain Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Spine Osteoarthritis Pain Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Spine Osteoarthritis Pain Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Spine Osteoarthritis Pain Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Spine Osteoarthritis Pain Drug Sales by Region in 2025 Figure 20. Global Spine Osteoarthritis Pain Drug Revenue by Region in 2025 Figure 21. North America Spine Osteoarthritis Pain Drug Market Size by Country in 2025 Figure 22. North America Spine Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 23. North America Spine Osteoarthritis Pain Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Spine Osteoarthritis Pain Drug Market Size by Country in 2025 Figure 28. Europe Spine Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Spine Osteoarthritis Pain Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Spine Osteoarthritis Pain Drug Market Size by Country in 2025 Figure 41. Asia Pacific Spine Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Spine Osteoarthritis Pain Drug Revenue Market Share by Country (2021-2032) Figure 43. China Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Spine Osteoarthritis Pain Drug Market Size by Country in 2025 Figure 52. South America Spine Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 53. South America Spine Osteoarthritis Pain Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Colombia Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Spine Osteoarthritis Pain Drug Market Size by Country in 2025 Figure 59. Middle East and Africa Spine Osteoarthritis Pain Drug Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Spine Osteoarthritis Pain Drug Revenue Market Share by Country (2021-2032) Figure 61. Egypt Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Spine Osteoarthritis Pain Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Spine Osteoarthritis Pain Drug Sales Market Share by Type (2021-2032) Figure 67. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2032) Figure 68. Global Spine Osteoarthritis Pain Drug Price (US$/unit) by Type (2021-2032) Figure 69. Global Spine Osteoarthritis Pain Drug Sales Market Share by Application (2021-2032) Figure 70. Global Spine Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2032) Figure 71. Global Spine Osteoarthritis Pain Drug Price (US$/unit) by Application (2021-2032) Figure 72. Spine Osteoarthritis Pain Drug Value Chain Figure 73. Spine Osteoarthritis Pain Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Spine Osteoarthritis Pain Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Injection
  • External
  • Oral
Applications
  • Medical Care
  • Personal Care
Companies covered
  • Abbott
  • TEVA
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Mylan
  • Eli Lilly
  • Hengrui Pharmaceutical
  • Pfizer
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Bayer
  • Tide Pharmaceutical
  • Iroko Pharmaceuticals
  • Horizon Pharma
  • Astellas Pharma
  • Almatica Pharma
  • Abiogen Pharma

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Spine Osteoarthritis Pain Drug Market Size (2021-2032)
  4. 2.2.2 Global Spine Osteoarthritis Pain Drug Sales (2021-2032)
  5. 2.2.3 Global Spine Osteoarthritis Pain Drug Market Average Price (2021-2032)
  6. 2.3 Spine Osteoarthritis Pain Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Injection
  9. 2.3.3 External
  10. 2.3.4 Oral
  11. 2.4 Spine Osteoarthritis Pain Drug by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Medical Care
  14. 2.4.3 Personal Care
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Spine Osteoarthritis Pain Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Spine Osteoarthritis Pain Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Spine Osteoarthritis Pain Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Spine Osteoarthritis Pain Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Spine Osteoarthritis Pain Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Spine Osteoarthritis Pain Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Spine Osteoarthritis Pain Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Spine Osteoarthritis Pain Drug, Established Date
  9. 3.9 Global Spine Osteoarthritis Pain Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Abbott
  2. 4.1.1 Abbott Company Information
  3. 4.1.2 Abbott Business Overview
  4. 4.1.3 Abbott Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Abbott Spine Osteoarthritis Pain Drug Product Portfolio
  6. 4.1.5 Abbott Recent Developments
  7. 4.2 TEVA
  8. 4.2.1 TEVA Company Information
  9. 4.2.2 TEVA Business Overview
  10. 4.2.3 TEVA Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 TEVA Spine Osteoarthritis Pain Drug Product Portfolio
  12. 4.2.5 TEVA Recent Developments
  13. 4.3 Sanofi
  14. 4.3.1 Sanofi Company Information
  15. 4.3.2 Sanofi Business Overview
  16. 4.3.3 Sanofi Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sanofi Spine Osteoarthritis Pain Drug Product Portfolio
  18. 4.3.5 Sanofi Recent Developments
  19. 4.4 Johnson and Johnson
  20. 4.4.1 Johnson and Johnson Company Information
  21. 4.4.2 Johnson and Johnson Business Overview
  22. 4.4.3 Johnson and Johnson Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Johnson and Johnson Spine Osteoarthritis Pain Drug Product Portfolio
  24. 4.4.5 Johnson and Johnson Recent Developments
  25. 4.5 Novartis
  26. 4.5.1 Novartis Company Information
  27. 4.5.2 Novartis Business Overview
  28. 4.5.3 Novartis Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Novartis Spine Osteoarthritis Pain Drug Product Portfolio
  30. 4.5.5 Novartis Recent Developments
  31. 4.6 Mylan
  32. 4.6.1 Mylan Company Information
  33. 4.6.2 Mylan Business Overview
  34. 4.6.3 Mylan Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Mylan Spine Osteoarthritis Pain Drug Product Portfolio
  36. 4.6.5 Mylan Recent Developments
  37. 4.7 Eli Lilly
  38. 4.7.1 Eli Lilly Company Information
  39. 4.7.2 Eli Lilly Business Overview
  40. 4.7.3 Eli Lilly Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Eli Lilly Spine Osteoarthritis Pain Drug Product Portfolio
  42. 4.7.5 Eli Lilly Recent Developments
  43. 4.8 Hengrui Pharmaceutical
  44. 4.8.1 Hengrui Pharmaceutical Company Information
  45. 4.8.2 Hengrui Pharmaceutical Business Overview
  46. 4.8.3 Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Hengrui Pharmaceutical Spine Osteoarthritis Pain Drug Product Portfolio
  48. 4.8.5 Hengrui Pharmaceutical Recent Developments
  49. 4.9 Pfizer
  50. 4.9.1 Pfizer Company Information
  51. 4.9.2 Pfizer Business Overview
  52. 4.9.3 Pfizer Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Pfizer Spine Osteoarthritis Pain Drug Product Portfolio
  54. 4.9.5 Pfizer Recent Developments
  55. 4.10 GlaxoSmithKline
  56. 4.10.1 GlaxoSmithKline Company Information
  57. 4.10.2 GlaxoSmithKline Business Overview
  58. 4.10.3 GlaxoSmithKline Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 GlaxoSmithKline Spine Osteoarthritis Pain Drug Product Portfolio
  60. 4.10.5 GlaxoSmithKline Recent Developments
  61. 4.11 Daiichi Sankyo
  62. 4.11.1 Daiichi Sankyo Company Information
  63. 4.11.2 Daiichi Sankyo Business Overview
  64. 4.11.3 Daiichi Sankyo Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Daiichi Sankyo Spine Osteoarthritis Pain Drug Product Portfolio
  66. 4.11.5 Daiichi Sankyo Recent Developments
  67. 4.12 Bayer
  68. 4.12.1 Bayer Company Information
  69. 4.12.2 Bayer Business Overview
  70. 4.12.3 Bayer Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Bayer Spine Osteoarthritis Pain Drug Product Portfolio
  72. 4.12.5 Bayer Recent Developments
  73. 4.13 Tide Pharmaceutical
  74. 4.13.1 Tide Pharmaceutical Company Information
  75. 4.13.2 Tide Pharmaceutical Business Overview
  76. 4.13.3 Tide Pharmaceutical Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Tide Pharmaceutical Spine Osteoarthritis Pain Drug Product Portfolio
  78. 4.13.5 Tide Pharmaceutical Recent Developments
  79. 4.14 Iroko Pharmaceuticals
  80. 4.14.1 Iroko Pharmaceuticals Company Information
  81. 4.14.2 Iroko Pharmaceuticals Business Overview
  82. 4.14.3 Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Iroko Pharmaceuticals Spine Osteoarthritis Pain Drug Product Portfolio
  84. 4.14.5 Iroko Pharmaceuticals Recent Developments
  85. 4.15 Horizon Pharma
  86. 4.15.1 Horizon Pharma Company Information
  87. 4.15.2 Horizon Pharma Business Overview
  88. 4.15.3 Horizon Pharma Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Horizon Pharma Spine Osteoarthritis Pain Drug Product Portfolio
  90. 4.15.5 Horizon Pharma Recent Developments
  91. 4.16 Astellas Pharma
  92. 4.16.1 Astellas Pharma Company Information
  93. 4.16.2 Astellas Pharma Business Overview
  94. 4.16.3 Astellas Pharma Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Astellas Pharma Spine Osteoarthritis Pain Drug Product Portfolio
  96. 4.16.5 Astellas Pharma Recent Developments
  97. 4.17 Almatica Pharma
  98. 4.17.1 Almatica Pharma Company Information
  99. 4.17.2 Almatica Pharma Business Overview
  100. 4.17.3 Almatica Pharma Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Almatica Pharma Spine Osteoarthritis Pain Drug Product Portfolio
  102. 4.17.5 Almatica Pharma Recent Developments
  103. 4.18 Abiogen Pharma
  104. 4.18.1 Abiogen Pharma Company Information
  105. 4.18.2 Abiogen Pharma Business Overview
  106. 4.18.3 Abiogen Pharma Spine Osteoarthritis Pain Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Abiogen Pharma Spine Osteoarthritis Pain Drug Product Portfolio
  108. 4.18.5 Abiogen Pharma Recent Developments
5 Global Spine Osteoarthritis Pain Drug Market Scenario by Region
  1. 5.1 Global Spine Osteoarthritis Pain Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Spine Osteoarthritis Pain Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Spine Osteoarthritis Pain Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Spine Osteoarthritis Pain Drug Sales by Region: 2027-2032
  5. 5.3 Global Spine Osteoarthritis Pain Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Spine Osteoarthritis Pain Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Spine Osteoarthritis Pain Drug Revenue by Region: 2027-2032
  8. 5.4 North America Spine Osteoarthritis Pain Drug Market Facts & Figures by Country
  9. 5.4.1 North America Spine Osteoarthritis Pain Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Spine Osteoarthritis Pain Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Spine Osteoarthritis Pain Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Spine Osteoarthritis Pain Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Spine Osteoarthritis Pain Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Spine Osteoarthritis Pain Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Spine Osteoarthritis Pain Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Spine Osteoarthritis Pain Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Spine Osteoarthritis Pain Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Spine Osteoarthritis Pain Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Spine Osteoarthritis Pain Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Spine Osteoarthritis Pain Drug Market Facts & Figures by Country
  41. 5.7.1 South America Spine Osteoarthritis Pain Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Spine Osteoarthritis Pain Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Spine Osteoarthritis Pain Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Spine Osteoarthritis Pain Drug Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Spine Osteoarthritis Pain Drug Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Spine Osteoarthritis Pain Drug Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Spine Osteoarthritis Pain Drug Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Spine Osteoarthritis Pain Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Spine Osteoarthritis Pain Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Spine Osteoarthritis Pain Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Spine Osteoarthritis Pain Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Spine Osteoarthritis Pain Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Spine Osteoarthritis Pain Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Spine Osteoarthritis Pain Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Spine Osteoarthritis Pain Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Spine Osteoarthritis Pain Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Spine Osteoarthritis Pain Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Spine Osteoarthritis Pain Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Spine Osteoarthritis Pain Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Spine Osteoarthritis Pain Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Spine Osteoarthritis Pain Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Spine Osteoarthritis Pain Drug Value Chain Analysis
  2. 8.1.1 Spine Osteoarthritis Pain Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Spine Osteoarthritis Pain Drug Production Mode & Process
  5. 8.2 Spine Osteoarthritis Pain Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Spine Osteoarthritis Pain Drug Distributors
  8. 8.2.3 Spine Osteoarthritis Pain Drug Customers
9 Global Spine Osteoarthritis Pain Drug Analyzing Market Dynamics
  1. 9.1 Spine Osteoarthritis Pain Drug Industry Trends
  2. 9.2 Spine Osteoarthritis Pain Drug Industry Drivers
  3. 9.3 Spine Osteoarthritis Pain Drug Industry Opportunities and Challenges
  4. 9.4 Spine Osteoarthritis Pain Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst